Replication-competent herpes simplex virus mediates destruction of neoplastic cells
A method for killing malignant brain tumor cells in vivo entails providing replication competent herpes simplex virus vectors to tumor cells. A replication competent herpes simplex virus vector, with defective expression of the γ34.5 gene and the ribonucleotide reductase gene, specifically destroys tumor cells, is hypersensitive to anti-viral agents, and yet is not neurovirulent.
1. A herpes simplex virus with a genome that comprises (i) an expressible non-herpes simplex virus nucleotide sequence encoding a cytokine capable of eliciting an immune response against a tumor cell, and (ii) an alteration in the γ34.5 gene such that no functional γ34.5 gene product is made, wherein the neurovirulence of said herpes simplex virus is attenuated.
2. The herpes simplex virus of claim 1 , further comprising at least one further gene alteration.
3. The herpes simplex virus of claim 2 , wherein said at least one further gene alteration is in the ribonucleotide reductase gene, such that no functional ribonucleotide reductase is made.
4. The herpes simplex virus of claim 3 , wherein said herpes simplex virus is G207 expressing the cytokine.
5. The herpes simplex virus of claim 1 , wherein an essential viral gene product of said virus is under the control of a tumor cell-specific promoter rather than its own viral promoter.
6. A composition comprising the herpes simplex virus of claim 1 and a pharmaceutically acceptable vehicle for said virus.
7. The herpes simplex virus of claim 5 , wherein said tumor cell-specific promoter is nestin promoter.
8. The herpes simplex virus of claim 5 , wherein said tumor cell-specific promoter is basic fibroblast growth factor promoter.
9. The herpes simplex virus of claim 5 , wherein said tumor cell-specific promoter is epidermal growth factor promoter.